MANKINDBSEMANKIND PHARMA LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 31 Aug, 2026 · 20:04 IST

Mankind Pharma completes sale of 100% stake in Broadway Hospitality subsidiary

Core Business DivestedStrategic Transactions View source PDFExplain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.4%Reaction day
₹2419.20
prior close
₹2381.40
announcement price
After-mkt
timing
Nifty Midcap 150market-1.2%-1.2% vs market
Pharmaceuticals peers, median of 175sector-0.3%-2.1% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Midcap 150 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.2
10m
-1.1
15m
-0.8
30m
-0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.4-1.2-1.2-0.3-2.1
Next day
-1.8-1.8+0.0-0.5-1.3
2d
-2.3-1.3-1.0+0.0-2.3
3d
-3.8-1.6-2.2+0.2-4.0
4d
-4.1-2.0-2.1+0.2-4.3
5d
-4.6-1.9-2.7+0.9-5.4
1w
-7.5-2.7-4.8+0.3-7.8
15d
+1.6-2.6+4.2+0.7+0.9
1m
+4.8-8.0+12.8-1.3+6.1
2m
—————
3m
—————
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 175Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma has completed the sale of its 100 percent stake in Broadway Hospitality Services Pvt Ltd to AKRK Projects LLP and its partners on August 31, 2026. Broadway was a wholly owned subsidiary of Mankind Pharma and has now ceased to be one. This follows the company earlier intimation dated July 11, 2026 announcing the proposed sale. Broadway operated in the hospitality sector, which is non-core for the pharma focused Mankind Pharma.

Likely market impact

Non-core hospitality subsidiary fully divested, allowing sharper focus on core pharma business. Likely minor positive for shareholders.